Acrivon Reports First Quarter 2026 Financial Results and Highlights Progress Towards Key 2026 Clinical Catalysts
The Phase 2b study ACR-368, designed for registration purposes, is making progress with a simultaneous interim analysis and data refresh planned for both arms of all-comer (biopsy-independent) serous endometrial cancer in the latter part of 2026.
Source: Unusual Whales The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments